Structured evidence table for Silicon Bone Health Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Silicon Bone Health Randomized Trial | OVCFs are associated with significant reductions in health-related quality of life, progressive spinal deformity, and increased mortality risk [,]. | 4 | Gazzeri Roberto (2026) | Oral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures |
| Silicon Bone Health Randomized Trial | Moreover, OVCFs substantially increase the risk of subsequent vertebral fractures by up to fivefold, initiating a cascade of skeletal fragility that further worsens long-term prognosis [,]. | 4 | Gazzeri Roberto (2026) | Oral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures |
| Silicon Bone Health Randomized Trial | 7 8 9 10 11 12 13 14 15 Most OVCFs are initially managed conservatively, and current international guidelines recommend non-operative treatment for stable fractures without neurological compromise [,,]. | 4 | Gazzeri Roberto (2026) | Oral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures |
| Silicon Bone Health Randomized Trial | 1 2 3 4 5 6 Osteoporotic vertebral compression fractures (OVCFs) are the most common manifestation of osteoporotic skeletal disease and represent a major global public health burden []. | 4 | Gazzeri Roberto (2026) | Oral Food Supplement with Bio-Activated Silicium and Vitamins D3 and K2 in the Conservative Management of Osteoporotic Vertebral Compression Fractures |
Source documents